borderline significanceP =0.052
At borderline significance, patients taking anti-CD38 or BCMA-targeting agents at the 4 th dose were more likely to have negative T-cell IGRA (adjusted OR 3.2, 95% CI: 1.0-10.7, P =0.052).
At borderline significance, patients taking anti-CD38 or BCMA-targeting agents at the 4 th dose were more likely to have negative T-cell IGRA (adjusted OR 3.2, 95% CI: 1.0-10.7, P =0.052).